A microRNA signature of response to erlotinib is descriptive of TGFβ behaviour in NSCLC
Abstract Our previous work identified a 13-gene miRNA signature predictive of response to the epidermal growth factor receptor (EGFR) inhibitor, erlotinib, in Non-Small Cell Lung Cancer cell lines. Bioinformatic analysis of the signature showed a functional convergence on TGFβ canonical signalling....
Main Authors: | Madeline Krentz Gober, James P. Collard, Katherine Thompson, Esther P. Black |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-017-04097-7 |
Similar Items
-
Deregulation of a Network of mRNA and miRNA Genes Reveals That CK2 and MEK Inhibitors May Synergize to Induce Apoptosis KRAS-Active NSCLC
by: Madeline Krentz Gober, et al.
Published: (2019-05-01) -
Novel therapeutic targets in NSCLC resistance to Erlotinib
by: Chater, Emily
Published: (2017) -
Erlotinib as the Second-line Treatment for NSCLC Patients of Stage IIIb/IV
by: Tian LI
Published: (2009-12-01) -
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
by: Kazuto Nishio, MD, PhD, et al.
Published: (2021-06-01) -
Erlotinib and Concurrent Chemoradiation in Pretreated NSCLC Patients: Radiobiological Basis and Clinical Results
by: Sara Ramella, et al.
Published: (2013-01-01)